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Azadirachta indica (common name: neem) leaves have been found to possess immunomodulatory, anti-inﬂammatory and anti-
carcinogenic properties. The present study evaluates anti-angiogenic potential of ethanol extract of neem leaves (EENL) in
human umbilical vein endothelial cells (HUVECs). Treatment of HUVECs with EENL inhibited VEGF induced angiogenic
response in vitro and in vivo.T h ein vitro proliferation, invasion and migration of HUVECs were suppressed with EENL. Nuclear
fragmentation and abnormally small mitochondria with dilated cristae were observed in EENL treated HUVECs by transmission
electron microscopy. Genome-wide mRNA expression proﬁling after treatment with EENL revealed diﬀerentially regulated genes.
Expression changes of the genes were validated by quantitative real-time polymerase chain reaction. Additionally, increase in the
expression of HMOX1, ATF3 and EGR1 proteins were determined by immunoblotting. Analysis of the compounds in the EENL
by mass spectrometry suggests the presence of nimbolide, 2 ,3 -dehydrosalannol, 6-desacetyl nimbinene and nimolinone. We
further conﬁrmed antiproliferative activity of nimbolide and 2 ,3 -dehydrosalannol in HUVECs. Our results suggest that EENL
by regulating the genes involved in cellular development and cell death functions could control cell proliferation, attenuate the
stimulatoryeﬀectsofVEGFandexertantiangiogeniceﬀects.EENLtreatmentcouldhaveapotentialtherapeuticroleduringcancer
progression.
1.Introduction
Cancerisprofoundlyinﬂuencedbythetumormicroenviron-
ment [1], which is a complex and highly dynamic environ-
ment, harboring a variety of host-derived cells involved in
tumor development and progression, including endothelial
cells, ﬁbroblasts, and innate and adaptive immune cells [2].
Tumor-associated endothelial cells form angiogenic vessels
by sprouting from existing vessels and recruit bone-marrow-
derived endothelial progenitor cells which provide nutrition
to support tumor growth. These cells are also the interface
between circulating blood cells, tumor cells, and the extra-
cellular matrix and control leukocyte recruitment, tumor
cell behavior, and metastasis formation. Under normal
conditionstheendothelialliningactsasabarrieragainstboth
leukocyte traﬃcking and cancer-cell transmigration [3].
However, inﬂammation causes cytoskeletal rearrangements
in endothelial cells, cancer cells, and leukocytes, potentially
priming them for eﬃcient migration [4]. Subtle changes in
endothelialcellsphenotypecouldbeeasilytransmittedtothe
tumorswithprofoundeﬀectsoncancerfate.Endothelialcells
can regulate diverse aspects of cancer cell function, including
proliferation, invasiveness, and metastasis [5].
Angiogenesis is a necessary process for tumor progres-
sion and has emerged as a valid therapeutic target for solid
malignancies [6]. Eﬀective inhibition of tumor angiogenesis2 Evidence-Based Complementary and Alternative Medicine
could provide crucial suppression of not only tumor growth
but also tumor metastasis; the development of agents in-
hibiting angiogenic processes has become a matter of focus.
The safety of the approved antiangiogenic agents (e.g., ba-
vacizumab, sunitnib, and sorafenib) is of special concern
when taking these agents for longer-term adjuvant or main-
tenance treatments [6]. Plant extracts and natural com-
pounds possess various bioactive phytochemicals, usually
targeting multiple signaling pathways, exhibit less toxicity
and thus ideal as alternative and complimentary forms
of cancer treatments that involve the dysregulation of
multiple genes [7]. This has prompted the recent testing
for anticancer potential of numerous plant extracts such
as those from green tea, grape seed, pomegranate juice,
soy, and garlic [8]. Pomegranate extract is an example
havingpotentialclinicaleﬀectsontreatingadvancedprostate
cancer by prolonging PSA doubling time [9]. One promising
medicinal plant is neem with an extensive history in the
traditional medicine practices of India and southeast Asia
[10]. Neem leaves contain multiple compounds such as
limonoids, nonterpenoids, phenolics, and ﬂavonoids that
may work simultaneously and/or synergistically to target
multiple pathways and suppress the cancer growth [11, 12].
Neem has been shown to cause anticancer, antioxidant,
wound-healing, and antimicrobial eﬀects [13, 14]. However,
there is currently no information reporting the potential for
neem extract to inhibit angiogenesis in cancer.
The current study is designed to evaluate the antian-
giogenic eﬀects of EENL. Our data revealed that EENL
inhibited in vitro and in vivo angiogenic responses, pro-
liferation, migration, and invasion of endothelial cells. To
better understand the mechanism of action behind the
neem leaf antiangiogenic eﬀects, genome-wide diﬀerential
transcriptomic analysis was performed. Using the results of
the analysis, we identiﬁed a set of target genes regulated
in endothelial cells after treatment with EENL and then
validated the mRNA expression changes and measured
the encoded protein expression levels. Further, we per-
formed liquid chromatography/time-of-ﬂight mass spec-
trometry (LC/TOF-MS) analysis to identify the compounds
in EENL. The two individual compounds nimbolide and
2 ,3 -dehydrosalannol present in EENL were further tested
to inhibit proliferation of HUVECs.
2.MaterialsandMethods
2.1. Ethanol Extraction of Neem Leaves. Neem tree leaves
harvested during the summer season were obtained from
NeemTreeFarms(Brandon,FL,USA).Ethanolextractofthe
neem leaves was prepared as described previously [15]. The
eﬀectoftheextractoncellviabilityandgeneexpressionlevels
described below were assessed to standardize the method of
extraction. We obtained consistent results with diﬀerent lots
of the extract.
2.2. Cell Line and Cell Culture. HUVECs derived from
single donors and cryopreserved at the end of passage
level-1 were purchased from BD biosciences (Bedford, MA,
USA). HUVECs were cultured in Biocoat endothelial cell
growth medium (BD Bioscience) supplemented with 5μgo f
epidermal growth factor (EGF) and 100mg of endothelial
cell growth supplement (ECGS). The cells were incubated in
a humidiﬁed atmosphere of 5% CO2 at 37◦Ca sd e s c r i b e d
previously [16]. The culture medium was changed every
other day and cells were harvested using Trypsin/EDTA
solution. Soybean trypsin inhibitor was used to inactivate
trypsin for subculturing the cells. For all the experiments
described below we used HUVECs before passage level-7.
2.3. Cell Viability Assay. HUVECs derived from single donor
were seeded into 96-well plates at a density of 3 × 103
p e rw e l lf o r2 4h o u r sa t3 7 ◦Ci na5 %C O 2 atmosphere
and treated with EENL (10 to 80.0μg/mL) or with the
vehicle controls (0.00125 to 0.01% DMSO) for 24 hours.
All the experiments were conducted with the HUVECs
derived from single donor obtained from BD biosciences.
In addition, we further tested the viability of HUVECs
pooled from multiple donors purchased from Invitrogen
(Carlsbad,CA,USA)usingtheneemcompounds.Nimbolide
was purchased from BioVision (Mountain View, CA, USA)
and 2 ,3 -dehydrosalannol was purchased from the Asthagiri
Herbal Research Foundation (Channai, Tamil Nadu, India).
A 50mM solution of these compounds was prepared in
dimethyl sulfoxide (DMSO) and stored in small aliquots
at −20◦C. HUVECs were incubated for 24 hours with
nimbolide (2 to 12μM) or 2 ,3 -dehydrosalannol (4 to
20μM) or with the corresponding vehicle controls (0.004
to 0.04% DMSO). Cell viability was then determined by
the colorimetric MTS assay using CellTiter 96 AQueous
One Solution Proliferation Assay System from Promega
(Madison, WI, USA), as previously described [17]. The
number of viable cells is directly related to the absorbance of
themedium,whenreadwithaspectrophotometerat490nm.
2.4.TransmissionElectronMicroscopy(TEM). HUVECswere
plated in 10cm plates and after reaching 60–70% conﬂuency,
they were treated for 24 hours with 20.0 and 40.0μg/mL
of EENL. Cells were ﬁxed with Trump’s ﬁxative (4%
paraformaldehyde with 1% glutaraldehyde in phosphate-
buﬀered saline, pH 7.2), scraped from plates and placed into
2% low melting agar. Processing was facilitated with the use
of a laboratory microwave oven (Pelco Biowave 3450, Ted
Pella, Inc., Redding, CA, USA). Following ﬁxation, cells were
stained with 1% osmium tetroxide and 2% uranyl acetate,
dehydrated through an ethanol series, and embedded into
Embed 812 resin. Following a 24-hour polymerization at
60◦C, 0.1μM ultrathin sections were poststained with lead
citrate. Micrographs were acquired using a Technai G212
Transmission Electron Microscope (FEI, Inc., Hillsboro,
OR, USA) equipped with a digital CCD camera (Advanced
Microscopy Techniques, Danvers, MA, USA).
2.5. Cell Migration and Invasion Assays. The in vitro cell
migration and invasion assays were performed using Fluo-
roBlock 24-multiwell insert plates (BD Biocoat angiogenesis
system). The insert plates were composed of a ﬂuorescenceEvidence-Based Complementary and Alternative Medicine 3
blocking PET membrane coated with human ﬁbronectin for
migration and Matrigel for invasion assays. HUVECs were
starved for 5 hours in CS-C medium without serum (Sigma-
Aldrich, St. Louis, MO, USA), supplemented with 0.1% BSA
for migration assay. HUVECs (1 × 104 cells for migration
and 0.5 × 104 cells for invasion) suspended in 250μLo fC S -
Cserum-freemediumsupplementedwithBSAformigration
and growth medium (2% serum) for invasion were treated
with EENL (10–80μg/mL) or vehicle control and seeded
ontotheupperinsertcompartmentofthetranswellchamber.
The lower chamber was ﬁlled with 2% serum containing
endothelial cell growth medium supplemented with chemo-
attractant (VEGF 100ng/mL). After incubating for 22 hours
the cells were postlabeled with Calcein AM ﬂuorescent dye.
Fluorescence of the invaded cells was read at 494/517nm.
Data were expressed as relative migration and invasion cell
number compared with the vehicle control of EENL in the
presence of VEGF.
2.6. Endothelial Cell Tube Formation Assay. The in vitro
tube formation assay was performed using Matrigel-coated
angiogenesis plates (BD Biocoat angiogenesis system) as
described [18]. HUVECs (4 × 105 cells/mL) suspended in
Biocoat endothelial cell growth medium (BD biosciences)
were preincubated in the presence of various concentrations
of EENL (10 to 80μg/mL) or the vehicle control and VEGF
(100ng/mL). The cells were seeded in a 96-well angiogenesis
plate (2 × 104 cells/well) and incubated for 17 hours at 37◦C
in a 5% CO2 incubator. The cells were labeled with Calcein
solution at 8μg/mL, and tube formation was observed
using ﬂuorescent microscope Axiovert 200M with Apotome
Module (Carl Zeiss MicroImaging, Inc.). Tube length was
measured using Image pro 6.2 software and the data were
e x p r e s s e da sr e l a t i v et u b el e n g t hc o m p a r e dw i t hv e h i c l e
control of EENL.
2.7. Measurement of Angiogenic Response In Vivo. The exper-
iments involving mice were conducted with the approval of
Executive Subcommittee of the Institutional Animal Care
and Use Committee of Mayo Clinic (approval ID: A-25209)
in compliance with the Association for Assessment and
Accreditation of Laboratory Animal Care International’s
expectations for animal care and use/ethics committees and
the investigators strictly followed the National Institutes of
Health guidelines for humane treatment of animals. Female
athymic nu/nu mice, 6-to-8 weeks of age, were obtained
from Charles River Laboratories (Wilmington, MA, USA),
and housed at the animal care facility as descried previously
[16]. After acclimatization for one week the animals were
used for the experiment. Angiogenic response in vivo was
examined with the directed in vivo angiogenesis assay kit
(Trivigen, Gaithersburg, MD, USA) as described [19]. In
brief, semiclosed angioreactors were ﬁlled with 20μLg r o w t h
factor reduced basement membrane matrix, 180μg of FGF-
2, 60ng of VEGF, and 2μg of heparin with or without 100μg
of EENL. The total volume of the mixture loaded in each
angioreactor was kept below 22μL. The angioreactors were
incubated at 37◦C for one hour to allow gel formation and
then implanted subcutaneously into the dorsal ﬂank of the
mice. Two angioreactors were implanted on each right and
left dorsal ﬂank of mice, respectively. For each group we used
5 mice, each mouse with 4 angioreactors. Group 1 was the
positive control without EENL, group 2 was the test with
EENL, group 3 was the negative control without VEGF, and
group 4 was the positive control for FGF. After 12 days,
angioreactors were removed and photographed. To quantify
the angiogenic response, basement membrane matrix/vessel
complex from each angioreactor was recovered and digested
withCellSpersetocollectthecells.Thesingle-cellsuspension
was labeled with ﬂuorescein-conjugated lectin-1 and the
ﬂuorescence was measured in a 96-well plate using Tecan
Spectraﬂuor plus microplate reader at 485nm.
2.8. Gene Expression Analysis and Validation. HUVECs were
treated with 20.0 and 40.0μg/mL of EENL or vehicle
control for 24 hours. RNA extraction, gene expression using
Human Genomic-U133-Plus2 oligonucleotide microarrays
(Aﬀymetrix, Santa Clara, CA, USA) and validation of
diﬀerentiallyregulatedgeneswasperformedbyTaqmanreal-
time PCR as described previously [15]. Ingenuity Pathway
Analysis (Ingenuity, Mountain View, CA, USA) was used for
evaluation of the biological functions of the diﬀerentially
expressed genes.
2.9. Protein Extraction and Western Blotting. HUVECs were
plated in 10cm plates and after reaching 60–70% conﬂuency
were treated for 24 hours with 20.0 and 40.0μg/mL of
EENL. Proteins were extracted from cells in modiﬁed RIPA
buﬀer and western blotting was performed using primary
antibodies against heme oxygenase-1 (HMOX1), activating
transcription factor 3 (ATF3), and early growth response-
1 (EGR1), (from Abcam Inc., Cambridge, MA, USA) and
horseradish peroxidase-conjugated secondary antibodies as
described previously [17]. Immunodetection was performed
by LumiGLO chemiluminescence detection system (Cell Sig-
naling, Danvers, MA, USA), in line with the manufacturer’s
instructions. GAPDH was used as loading control.
2.10. LC/TOF-MS Analyses. LC/TOF-MS analysis was per-
formed as described earlier [15] with a change in the mobile
phases using mobile phase A containing water with, 0.1%
formic acid, and 0.01% sodium acetate and mobile phase
B acetonitrile. Separation was achieved by using a gradient
from 65% to 90% mobile phase B over 10 minutes then
holding at 90% B for 15 minutes. The scan range for data
acquisition was 250–1200m/z range. The formation of an
even electron sodium adduct in the source was utilized to
provide increased selectivity for the tetranortriterpenoids
[20] present in the EENL.
2.11.StatisticalAnalysis. Thequantitativedataofcontinuous
variables were expressed as mean ± SD. Statistical signiﬁ-
cancewastestedbyonewayanalysisofvariance.Fiftypercent
inhibition concentration (IC50) values were calculated by
Probit regression. Partek Genomics suite 6.4 was used to4 Evidence-Based Complementary and Alternative Medicine
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Figure 1:InhibitionofendothelialcelltubeformationwithEENLtreatment.HUVECswereseededinaMatrigel-coatedplateinthepresence
of 10–80μg/mL of EENL or the vehicle control and VEGF (100ng/mL). After incubation for 17 hours the cells were labeled with Calcein
solution and tube images were taken at 2.5x magniﬁcation. The experiments were repeated twice in triplicate and the representative tube
images were shown. (a) Vehicle control treated cells. (b) Cells treated with 10μg/mL of EENL. (c) Cells treated with 20μg/mL of EENL. (d)
Cells treated with 40μg/mL of EENL. (e) Cells treated with 60μg/mL of EENL. (f) Cells treated with 80μg/mL of EENL. (g) Tube length was
measured using Image pro 6.2 software and the mean ± SD of two experiments with each performed in triplicate were shown (∗P<0.05).
analyze the genomic data. A P value <0.05 was considered
statistically signiﬁcant.
3. Results
3.1. EENL Impairs Formation of Tubes In Vitro and Vascular
Structure In Vivo. As tube formation represents one of the
late stages of angiogenesis, we evaluated the eﬀect of
EENL on in vitro tube formation of HUVECs plated on
a matrigel substratum. EENL treatment inhibited tube
formation and the tube lengths were signiﬁcantly reduced
with 20 to 80μg/mL of EENL (Figure 1). To substantiate
the in vitro data, we further studied the eﬀect of EENL
on angiogenic response in mice. Semiclosed angioreactors
ﬁlled with extracellular matrix containing angiogenic factors
(heparin, FGF2, and VEGF) with or without EENL were
implanted subcutaneously into the dorsal ﬂank of athymic
nude mice. The data presented was obtained from 5 mice
per group, each mouse implanted with 4 angioreactors from
theexperimentsperformedinduplicates.Wefoundapparent
vascular structures after 12 days of implantation in the
angioreactors of group 1 mice with angiogenic factors in
absence of EENL. From the total of 20 angioreactors in
ﬁve mice from group 1, signiﬁcant vascular structure was
found in 16 angioreactors, whereas vascular structure was
not observed in 4 angioreactors that were dislocated from
the original position of implantation. The formation of
vascular structures induced by the angiogenic factors were
signiﬁcantly inhibited in the presence of EENL in the all the
angioreactors of group 2 mice. No vascular structures were
observed in angioreactors that were ﬁlled with extracellular
matrix without angiogenic factors in the presence or absence
ofEENLingroup3andgroup4mice,respectively(Figure 2).
3.2. EENL Inhibit the Proliferation, Migration, and Invasion of
Endothelial Cells In Vitro. We performed viability assays to
analyzetheeﬀectofEENLonHUVECs.Theantiproliferative
activity of EENL was measured by MTS assay. Vehicle
treated cells were included as a control. EENL exhibited
a dose-dependent inhibition of cell growth with an IC50
of 40.0μg/mL (Figure 3(a)), where IC50 is the inhibition
concentration at which a 50% inhibition of cell growth is
observedat24hoursoftreatment.Endothelialcellmigration
andinvasion,whichoccurthroughchemotaxis,arenecessaryEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: (a) Suppression of vascular growth in the angioreactors with EENL treatment. Angioreactors ﬁlled with extracellular matrix
containing angiogenic factors (180μg of FGF-2, 60ng of VEGF, and 2μg of heparin) and in presence or absence of 100μg of EENL were
implanted subcutaneously into the dorsal ﬂank of 6-week-old athymic nude mice each. Two angioreactors were implanted on each side of
the dorsal ﬂank, a total of four angioreactors per mice and ﬁve mice per group were used. After 12 days the angioreactors were removed and
photographed. Signiﬁcant vascular structure is observed in 16 angioreactors of group 1 mice with VEGF. EENL signiﬁcantly inhibited the
VEGF-induced angiogenic response in group 2 mice in a total of 20 angioreactors. Vascular structure was signiﬁcantly inhibited in all the
angioreactors in group 3 and group 4 mice with EENL not containing VEGF and in the negative control without VEGF. (b) Measurement
of the angiogenic responses by FITC-lectin staining of the cell pellet recovered from the angioreactors. Data are the mean ± SD from
experiments repeated two times (∗P<0.05).
for angiogenesis. We used ﬁbronectin and matrigel Biocoat
angiogenesis system to mimic the microenvironment in vivo
for migration and invasion of the endothelial cells. EENL
treatments signiﬁcantly reduced migration and invasion of
HUVECs (Figure 3(b)). The mean inhibitory rates with 10,
20, 40, 60, and 80μg/mL of EENL were 22%, 37%, 65%, 80%
and 84% for migration and 51%, 70%, 86%, 89%, and 93%
for invasion, respectively.
3.3. EENL Induces Ultrastructural Changes in HUVECs. We
observed changes in the morphology of EENL-treated cells
underlightmicroscope,whichpromptedustofurtherexam-
ine the ultrastructural changes by TEM. EENL treatment
resulted in signiﬁcant elongation of the cells. Fragmented
nuclei, abnormally small mitochondria with dilated fewer
cristae, and vacuolization were observed after treatment of
HUVECs with 40.0μg/mL of EENL (Figure 4). These results
indicate that EENL induces changes in the cellular function
and inhibits cell proliferation.
3.4. EENL Regulates Gene Expression Proﬁles in HUVECs.
To identify the regulation of genes in HUVECs by EENL
treatment, we performed high-resolution whole-genome
proﬁling using an Aﬀymetrix microarray mRNA expres-
sion platform. The gene expression proﬁling of HUVECs
treated with 20 and 40μg/mL of EENL for 24 hours
showed signiﬁcant upregulation of 1182 and 3169 genes
and downregulation of 1247 and 1893 genes (>2f o l d ) .
Using the Ingenuity Pathways Knowledge Base, the inde-
pendently up- and downregulated genes were mapped for
the associated molecular and cellular functions. The most
enriched functions in the upregulated genes are cell death
and cell morphology, and in the downregulated genes are
cell cycle, cellular assembly, and organization, and DNA
replication, recombination, and repair, respectively. These
functions indicate that EENL may play a signiﬁcant role in
inhibition of cell growth.
3.5. EENL Increases the RNA and Protein Expression Levels of
HMOX1,ATF3,andEGR1inHUVECs. Toconﬁrmthealter-
ationsofgeneexpression,wevalidatedthemRNAexpression
levels of 30 upregulated and 30 downregulated genes for
Taqman real-time PCR analysis. The RNA expression levels
of the validated up- and downregulated genes treated with
20.0 and 40.0μg/mL of EENL support the ﬁndings obtained
from the microarray experiments (Tables 1(a) and 1(b)).
We selected 3 signiﬁcantly upregulated genes to conﬁrm
protein expression by western blot analysis. Our results
revealed signiﬁcant increase of the HMOX1, ATF3 and EGR1
protein levels treated with 20 and 40μg/mL of the EENL
(Figure 5) which are consistent with the increase in the
RNA expression levels. With the consistency of our results6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Inhibition of proliferation, migration and invasion of endothelial cells after treatment with EENL. HUVECs were treated for
24 hours with 10.0 to 80.0μg/mL of EENL or vehicle as control. (a) The antiproliferative eﬀect of EENL was evaluated using the MTS
viability assay. (b) Cell migration and invasion were assessed using ﬁbronectin and Matrigel-coated FluoroBlock 24-multiwell insert plates,
respectively. Experiments were performed in triplicate and the data were expressed as the mean ± SD of the triplicate determinations of a
representative experiment in % cell viability of vehicle-treated cells (100%) (∗P<0.05).
from validation of upregulated genes, we consider that these
results could support our microarray data for the validity of
the downregulated genes.
3.6. Identiﬁcation of Neem Compounds in the EENL.
L C/T OF -MSanal y siswaspe rf o rmedasd escribedearlie r[15]
with the modiﬁcation by including alkali cation sodium
acetate to enhance the identiﬁcation of the potential active
compounds in the EENL. Our analysis indicated mass spec-
tral peaks that appear to match the calculated monoisotopic
masses of known neem leaf compounds including nimbolide
and 2 ,3 -dehydrosalannol as standards. The mass spectrum
of the peaks includes protonated sodium adducts of the
standards. We subtracted the mass of sodium, 22.9898,
from each peak. The calculated monoisotopic mass of
nimbolide is 466.199 (molecular formula: C27H30O7)a n d
for 2 ,3 -dehydrosalannol is 554.2880 (molecular formula:
C32H42O8).Theobservednimbolidestandardshowedamass
spectrum with a major peak [M+Na]+ at 489.204m/z and
a lesser intensity peak [M+H]+ at 467.211m/z. Subtracting
the mass of sodium from the observed 489.204m/z results
in a monoisotopic mass of 466.231, and subtracting the
mass of hydrogen from the observed 467.221m/z results
in a monoisotopic mass of 466.213. These adjusted values
are in close agreement with the calculated monoisotopic
mass for nimbolide. The observed 2 ,3 -dehydrosalannol
standard showed a mass spectrum with a major peak at
577.2780m/z. Subtracting the mass of sodium from the
observed 577.2780m/z results in the calculated monoiso-
topic mass of 554.288. This adjusted value is in close agree-
ment with the calculated monoisotopic mass for the 2 ,3 -
dehydrosalannol. The total ion chromatogram of the EENL
depicts 4 signiﬁcant peaks, based on the intensity. These
peakswerelabeled1,2,3,and4;theassociatedmajorionsfor
the peaks are 475.2105m/z, 489.1891m/z, 463.2094m/z, and
577.2775m/z, respectively. After subtracting for the mass of
as o d i u mi o n ,t h em a j o ra d j u s t e dm a s sf o rp e a k s1 ,2 ,3 ,a n d
4 are 452.2210, 466.199, 440.220, and 554.288, respectively.
T h e s ea d j u s t e dm a s s e sf r o mp e a k2a n dp e a k4a r ei nc l o s e
agreement with the observed masses of the nimbolide and
2 ,3 -dehydrosalannol standard and suggesting that they are
compounds of EENL. The calculated monoisotopic mass for
the compound nimolinone (C30H44O3) is 452.3290 and 6-
desacetyl nimbinene (C26H32O6) is 440.2199. The observed
mass spectra for nimolinone and 6-desacetyl nimbinene
show major monoisotopic masses of 452.2220 and 440.2195,
respectively. The mass measurements for the dominant
monoisotopic masses observed for peaks 1 and 3 are in
agreement with the calculated monoisotopic masses of
nimolinone and 6-deacetyl nimbinene, which suggests their
presence in EENL. The EENL, the nimbolide standard,
and the 2 ,3 -dehydrosalannol standard were analyzed in
duplicate representative chromatograms and spectra were
shown in Figure 6.Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Ultrastructural changes in the HUVECs after treatment with 40μg/mL of EENL or vehicle for 24 hours observed under TEM.
Vehicle-treated cells were used as control. The experiments were repeated in duplicates, and the representative images were shown. (a)
Vehicle-treated cells showing morphological structure of HUVECs at 1650x. (b) Mitochondria indicated as M, and the endoplasmic
reticulum as ER, in the vehicle treated cells at 6700x. (c)–(f) Depict cells treated with EENL. (c) Morphological change showing elongated
cells at 1650x. (d) Abnormally small round mitochondria with fewer dilated cristae at 2100x. (e) Multivesicular bodies indicated as V, in the
cells undergoing deterioration at 3000x. (f) Fragmented nuclei indicated as N, and the vacuolization in cells at 1100x.
3.7. Nimbolide and 2 ,3 -Dehydrosalannol Inhibit the Prolifer-
ation of HUVECs. We further tested the neem compounds
to inhibit proliferation of HUVECs pooled from multiple
donors. A dose-dependent inhibition of HUVECs growth
was observed with an IC50 of 2.0μM for nimbolide and
6.0μMf o r2  ,3 -dehydrosalannol after 24 hours of treatment
(Figure 7).Ourresultssuggestthattheantiproliferativeeﬀect
ofEENLcouldbearesultoftheeﬀectofnimbolideand2 ,3 -
dehydrosalannol.
4. Discussion
This study is focused on the use of the extract because of
combining the eﬀects of the compounds in EENL which
could have multitargeted approach for regulation of multiple
signaling pathways in cancer progression. Cytotoxic and
antitumor eﬀects of neem leaf extracts have been reported in
a panel of cancer cell lines [21, 22]. In our previous study,
we have demonstrated antiproliferative activity of EENL
in vitro in prostate cancer cell lines and antitumor activity
in vivo in prostate cancer xenograft models [15]. In this
study we evaluated the eﬀect of EENL on angiogenesis by
assessing the tube formation of endothelial cells using a
matrigel culture system. We observed that EENL inhibited
VEGF-inducedinvitrotubeformationofHUVECsinadose-
dependentmanner(Figure 1).Moreover,wehaveshownthat
EENL is able to block development of vasculature in vivo
induced by angiogenic factors which is essential for new
vessel development that leads to tumor cell proliferation
and invasion (Figure 2). These results suggest that antian-
giogenesis activity of EENL is associated with inhibition of
VEGF activity and EENL can be recognized as a therapeutic
candidate of anticancer drugs.
We further explored the eﬀect of EENL on proliferation,
invasion, and migration of endothelial cells. The extent of
HUVECs growth inhibition was measured by MTS assay
which was used to determine the number of viable cells
in proliferation. EENL treatment signiﬁcantly inhibited the
growth of HUVECs (Figure 3(a)). Furthermore, migration
andinvasionassaysshowedthatHUVECstreatedwithEENL
showed markedly attenuated migration and invasion in a
concentration-dependent manner (Figure 3(b)). Mitochon-
dria are key organelles in conversion of energy, regulation
of cellular signaling, and ampliﬁcation of programmed8 Evidence-Based Complementary and Alternative Medicine
Table 1: (a) Upregulation and (b) downregulation in the RNA expression levels of 30 genes in HUVECs treated with 20.0 and 40.0μg/mL
of EENL for 24 hours, validated by real-time PCR. The endogenous GAPDH mRNA levels were measured as internal controls. Mean ± SD
of the fold change in the expression levels of genes compared with the respective vehicle controls were shown. Assay IDs of the genes used
for validation were from Applied Biosystems. Accession number and major molecular function for each gene are also shown.
(a)
Gene Fold upregulation (20μg/mL) Fold upregulation (40μg/mL) Assay ID Function
AKR1B10 17.68 ±3.25 48.31 ±8.68 Hs00252524 m1 Aldo-keto reductase activity
AKR1C1 6.70 ± 1.51 23.13 ±5.43 Hs00413886 m1 Oxidoredutase activity
AKR1C2 2.95 ± 0.55 23.31 ±5.07 Hs00912742 m1 Oxidoredutase activity
AKR1C3 2.73 ± 0.87 4.47 ±2.67 Hs00366267 m1 Oxidoredutase activity
ALDH3A2 2.01 ± 1.33 3.97 ±2.96 Hs00166066 m1 Aldehyde dehydrogenase
ALOX5 7.74 ± 2.50 1.97 ±1.42 Hs01095330 m1 Lipoxygenase activity
ATF3 86.64 ± 12.44 277.09 ±16.31 Hs00231069 m1 Transcription factor
CHAC1 54.21 ±4.2 156.95 ±14.98 Hs00225520 m1 Protein binding
CLU 2.53 ± 1.04 4.47 ±2.44 Hs00156548 m1 Protein binding
CSTA 4.58 ± 0.42 9.71 ±2.05 Hs00193257 m1 Protease binding
DDIT3 27.43 ±8.54 203.64 ±20.65 Hs00358796 g1 Nucleic acid binding
DMRT1 6.68 ± 1.45 21.91 ±3.11 Hs00232766 m1 Transcription factor
EGF 10.27 ±4.08 3.52 ±1.80 Hs01099999 m1 Signal transducer
EGR1 4.06 ± 1.67 87.38 ±15.36 Hs00152928 m1 Transcription factor
FOXC1 1.96 ± 1.24 5.91 ±3.68 Hs00559473 s1 Transcription factor
GCLM 3.48 ± 1.76 15.00 ±9.08 Hs00157694 m1 Glutamate-cysteine ligase
GPNMB 4.75 ± 0.53 38.43 ±6.90 Hs01095669 m1 Integrin binding
HMOX1 11.01 ±2.30 26.19 ±5.21 Hs01110251 m1 Heme oxygenase activity
ID2 4.48 ± 1.09 19.82 ±4.24 Hs00747379 m1 Transcription repressor
JDP2 5.56 ± 2.14 24.51 ±3.22 Hs00185689 m1 Transcription factor
LAMP3 6.08 ± 2.82 2.35 ±1.09 Hs00180880 m1 Integral to membrane
LY96 2.14 ± 0.23 3.82 ±2.42 Hs00209771 m1 Receptor activity
PEG3 21.38 ±8.36 87.45 ±30.33 Hs00377844 m1 Transcription factor
S100P 102.62 ±31.88 570.45 ±45.47 Hs00195584 m1 Calcium-dependent protein
SESN2 7.34 ± 4.98 23.62 ±6.63 Hs00230241 m1 Cell cycle arrest
SPINK1 247.34 ±23.27 465.02 ±53.98 Hs00162154 m1 Endopeptidase inhibitor
SPRR1A 4.22 ± 4.49 70.57 ±20.12 Hs00954595 s1 Structural molecule
TRIM16 2.08 ± 1.19 4.32 ±2.56 Hs00414879 m1 DNA binding
TUBA1A 2.06 ± 1.27 3.46 ±0.80 Hs00362387 m1 Structural molecule
WDR19 2.80 ± 1.32 9.43 ±4.26 Hs00228414 m1 Transmembrane signaling
(b)
Gene Fold downregulation 20μg/mL Fold downregulation 40μg/mL Assay ID Function
ANKRD12 3.83 ±1.84 21.63 ±6.80 Hs00209530 m1 Ion channel inhibitor
ASPM 2.36 ±0.63 5.69 ±2.34 Hs00996458 m1 Calmodulin binding
CDC2 5.50 ±2.22 9.39 ±4.12 Hs00938777 m1 Protein binding
CDC25A 15.65 ±3.26 2.09 ±1.78 Hs00947994 m1 Phosphatase activity
CDCA4 7.98 ±2.45 3.34 ±1.85 Hs00743989 s1 Cell division
CENPE 78.27 ±25.90 52.49 ±16.37 Hs00156507 m1 Chromatin binding
CHEK1 24.20 ±3.23 60.16 ±29.80 Hs00176236 m1 Protein Kinase
COL12A1 3.62 ±0.59 2.64 ±1.23 Hs00329355 s1 Structural molecule
DLGAP5 12.34 ±5.89 4.78 ±2.63 Hs00207323 m1 Phosphatase activity
DPP4 15.39 ±4.21 15.78 ±2.62 Hs00175218 m1 Aminopeptidase
DTL 3.88 ±1.40 1.55 ±0.80 Hs00978565 m1 Protein binding
E2F8 75.55 ±30.92 80.34 ±19.30 Hs00226635 m1 Transcription factor
EBP 9.75 ±3.21 3.26 ±1.05 Hs00198130 m1 Sterol isomeraseEvidence-Based Complementary and Alternative Medicine 9
(b) Continued.
Gene Fold downregulation 20μg/mL Fold downregulation 40μg/mL Assay ID Function
FBXO5 4.25 ±2.17 3.75 ±0.54 Hs00559989 m1 Protein binding
FOLH1 5.92 ±2.39 5.23 ±1.31 Hs00379515 m1 Carboxypeptidase
HIST1H4C 8.34 ±5.41 2.73 ±0.73 Hs00543883 s1 DNA binding
HSP90B1 26.21 ±12.03 30.88 ±13.74 Hs00427665 g1 Nucleotide binding
ITGAV 13.50 ±2.31 2.68 ±1.86 Hs00233790 m1 Receptor
KIF14 1.93 ±1.24 15.28 ±4.89 Hs00208408 m1 Microtubule motor
MAD2L1 5.55 ±3.25 7.83 ±2.16 Hs01554515 g1 Protein binding
METAP2 5.04 ±1.20 15.45 ±5.21 Hs01127366 m1 Aminopeptidase
NRIP1 24.88 ±6.20 45.47 ±14.54 Hs00942766 s1 Transcription coactivator
POLA1 15.62 ±3.22 4.39 ±2.87 Hs00213524 m1 Nucleotide binding
PRIM2 11.83 ±5.41 2.32 ±0.33 Hs00386277 m1 DNA primase
RRM1 5.87 ±1.72 11.23 ±4.21 Hs01040698 m1 Ribonucleoside
diphosphate reductase
SKP2 17.52 ±11.90 16.43 ±4.23 Hs00180634 m1 Ubiquitin-protein ligase
TOP2A 15.53 ±3.89 10.34 ±2.11 Hs01032127 g1 Topoisomerase activity
TOP2B 2.03 ±1.48 2.25 ±0.79 Hs00172259 m1 Topoisomerase activity
TPR 1.35 ±1.91 4.66 ±1.30 Hs00162918 m1 Protein kinase
UHRF1 10.73 ±2.84 3.41 ±1.52 Hs00273589 m1 Transcription factor
ATF3
GAPDH
   0                          20                             40
HMOX-1
EENL (µg/mL)
EGR-1
Figure 5:OverexpressionofHMOX1,ATF3,andEGR1inHUVECs
after treatment with 20.0 and 40.0μg/mL of EENL for 24 hours.
Protein levels were measured with speciﬁc antibodies by western
blot analysis; GAPDH was the loading control. Vehicle-treated cells
were used as control. The experiments were repeated in triplicates,
and the representative blot was shown.
cell death. A growing body of evidence shows changes in
mitochondrial shape are related to its altered metabolic
state aﬀecting the regulation of cellular functions [23].
Ultrastructural changes in the HUVECs observed by TME
suggest that EENL plays a vital role in altering the cellular
functions(Figure 4).Furtherstudiesarerequiredtoelucidate
the mechanism of action of EENL on the inhibition the cell
growth.
In order to identify the molecular targets involved in
mediating the eﬀect of EENL in endothelial cells, we
used genome-wide gene expression microarray analysis.
HUVECs showed a signiﬁcant upregulation of 1182 genes
and downregulation of 1247 genes after treatment with
20.0μg/mL of EENL, and 3169 upregulated genes and
1893 downregulated genes with 40.0μg/mL of EENL. We
further validated the expression of 30 upregulated and 30
downregulated genes by quantitative real-time PCR. There
was a signiﬁcant upregulation of the genes ALDH3A2,
ALOX5, ATF3, CLU, EGF, EGR1, FOXC1, GCLM, HMOX1,
JDP2, LY96, PEG3, S100P, and SPRR1A. These genes are
associated with kidney failure, renal disease, and urological
disease [24]. Signiﬁcant up-regulation was also conﬁrmed
for AKR1B10, AKR1C1, AKR1C2, AKR1C3, CHAC1, CSTA,
DDIT3, DMRT1, GPNMB, ID2, LAMP3, SESN2, SPINK1,
TRIM16, and TUBA1A. These genes are involved in cellular
development and cell death functions [25]. The majority
of the downregulated genes, including ANKRD12, ASPM,
CDC25A, CDCA4, CENPE, CHEK1, DLGAP5, DPP4, DTL,
EBP, E2F8, FBXO5, FOLH1, HIST1H4C, HSP90B1, ITGAV,
KIF14, MAD2L1, METAP2, NRIP1, POLA1, PRIM2, SKP2,
TOP2A, TOP2B, TPR, and UHRF1, are associated with cell
cycle function and cancer development [26, 27]. All these
validated upregulated and downregulated genes have been
shown to be down-regulated and up-regulated, respectively
(Tables 1(a) and 1(b)), in various cancer tissues, as shown
in Oncomine microarray data base [28]. This again suggests
EENL could induce an inhibitory eﬀect on cancer growth
and should be further considered for the prevention and
treatment of cancer.
T oc o r r e l a t eg e n ee x p r e s s i o nc h a n g e sw i t hp r o t e i nl e v e l s ,
we selected 3 upregulated genes HMOX1, ATF3, and EGR1
for western blot analysis. HMOX1, an enzyme degrading
heme to carbon monoxide, iron, and biliverdin, has been
recognized as playing a crucial role in cellular defense
against stressful conditions [29]. Although the expression
of HMOX1 is low in most tissues, a large number of plant10 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Mass spectrometric analysis of the standards nimbolide and 2 ,3 -dehydrosalannol and ethanol extract of neem leaves (EENLs).
(a) The mass spectrum of the nimbolide standard depicts the monoisotopic [M + Na]+ ion 489.204m/z and the [M + H]+ ion 467.221m/z.
(b) The mass spectrum of the 2 ,3 -dehydrosalannol depicts the monoisotopic [M+Na]+ ion 577.2780m/z. (c) The total ion chromatogram
of EENL. (c1) The mass spectrum of the peak 1 depicts the dominant monoisotopic ion 475.2105m/z, at a retention time of 11.68 minutes.
Subtracting the mass of sodium (22.9898) from the observed mass results in a mass is suggestive by mass alone as nimolinone. (c2) The
mass spectrum of the peak 2 depicts the dominant monoisotopic ion 489.1891m/z, at a retention time of 11.91 minutes. After subtracting
the sodium mass, this is suggestive by mass and retention time as nimbolide (c3) The mass spectrum of the peak 3 depicts the dominant
monoisotopic ion 463.2094m/z, at a retention time of 12.12 minutes. Subtracting the mass of sodium from the observed mass results in
a mass is suggestive by mass alone as 6-desacetyl nimbinene. (c4) The mass spectrum of the peak 4 depicts the dominant monoisotopic
ion 577.2775m/z, at a retention time of 12.35 minutes. After subtracting the sodium mass, this is suggestive by mass and retention time
as 2 ,3 -dehydrosalannol. A comparison of the spectra of the nimbolide and 2 ,3 -dehydrosalannol standards to the spectra from the EENL
peaks suggests that peaks 2 and 4 are nimbolide and 2 ,3 -dehydrosalannol, respectively.
extracts and pharmacological compounds (e.g., green tea,
curcumin, and statins) have been demonstrated to induce
HMOX1 [30–32]. Pharmacologic inhibition of HMOX1
induces marked leukocyte inﬁltration and enhances VEGF-
induced angiogenesis [33]. Overexpression of HMOX1 in
prostate cancer cells downregulated the MMP9 expression
and decreased the invasive potential [34]. The inhibition
of invasion and migration of HUVECs following EENL
treatment could be the result of a highly signiﬁcant increase
intheRNAandproteinexpressionlevelsofHMOX1(Table 1
and Figure 5). Under prolonged expression of HMOX1 the
released iron, carbon monoxide, biliverdin, and bilirubin
from the HMOX1 activity may attenuate the stimulatory
eﬀects of VEGF and exert antiangiogenic eﬀect [35]. The
induction of HMOX1 by EENL treatment could be the
possible mechanism to attenuate the excess formation of
blood vessels in inﬂammatory angiogenesis of the cancer.
ATF3 is a novel stress-activated regulator of p53 protein
stability and function [36]. It provides the cell with a means
of responding to a wide range of environmental insult, thus
maintaining DNA integrity and protecting the cell against
transformation [37]. ATF3 has been demonstrated to play
a role in apoptosis and proliferation, two cellular processes
critical for cancer progression [38]. Enforced expression
of ATF3 can restore p53 activity and induce apoptosis
of cells [39]. EENL treatment increased the expression of
ATF3 in HUVECs. Targeting ATF3 expression through EENL
could be a promising strategy for cancer therapy. EGR-1
is an immediate early gene that is rapidly and transiently
induced by many stimuli, including hypoxia, shear stress,
and injury [40]. EGR-1 controls the expression of a wide
v a r i e t yo fg e n e s ,m a n yo fw h i c hp l a yap i v o t a lr o l ei n
the regulation of cell growth, diﬀerentiation, and apoptosis
[41]. However, although several studies have shown EGR-
1 promotes cancer progression, there is increasing evidence
that EGR-1 may also exerts tumor suppression [42, 43]. In
leukemia, EGR-1 has been implicated in the apoptosis of
myeloma cells via interaction with c-JUN while it behaves
as a tumor suppressor against the oncogenes E2F-1 and
c-MYC [44]. EGR-1 activation by EGF inhibited MMP9
expression and lymphoma growth [45]. EENL induced
signiﬁcant upregulation of EGR-1 expression in endothelial
cells (Table 1 and Figure 5) suggesting that EGR1 might
have negative eﬀects on endothelial cells. Further studies are
needed to elucidate the role of EGR-1 upregulation on the
endothelial cell function.
Analysis of the compounds in EENL by LC/TOF-MS in-
cluding sodium acetate in the mobile phase revealed 4 major12 Evidence-Based Complementary and Alternative Medicine
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Figure 7: Inhibition of proliferation of endothelial cells after treatment with (a) nimbolide and (b) 2 ,3 -dehydrosalannol. HUVECs were
treated for 24 hours with nimbolide (2–12μM) or 2 ,3 -dehydrosalannol (4–20μM) or vehicle as control. The antiproliferative eﬀect of the
two compounds was evaluated by using the MTS viability assay. Experiments were performed in triplicate and the data were expressed as the
mean ± SD of the triplicate determinations of a representative experiment in % cell viability of vehicle-treated cells (100%) (∗P<0.05).
p e a k sw h i c hs u g g e s t2  ,3 -dehydrosalannol, nimbolide, 6-
desacetyl nimbinene, and nimolinone as the major com-
pounds in the EENL (Figure 6). The formation of an even
electron sodium adduct in the source was utilized to provide
increasedselectivityforthetetranortriterpenoids.Compared
to the formation of the protonated adduct as presented
earlier [15], the present data reveals that addition of the basic
ion can pick up nimbolide present in the EENL. Further
testing revealed that nimbolide and 2 ,3 -dehydrosalannol
inhibited HUVECs proliferation (Figure 7), suggesting that
these compounds contribute to the antiproliferative activity
of EENL.
In conclusion, these ﬁndings suggest that EENL con-
taining the compounds nimbolide, 2 ,3 -dehydrosalannol, 6-
desacetyl nimbinene, and nimolinone inhibits proliferation,
migration, invasion and angiogenesis response of HUVECs.
We used genome-wide proﬁling approach to identify the
genes associated with multiple biological pathways as poten-
tial targets of EENL, and demonstrated the upregulation
of the HMOX1, ATF3, and EGR-1 protein expression in
HUVECs. Over-stimulation of HMOX1 production could
be one of the contributing factor for inhibition of VEGF
induced angiogenesis. Our study indicates the importance
for further validation of the antiangiogenic potential in pre-
clinicalmodelsandinclinicaltrials,forsuccessfultranslation
of nontoxic neem treatment into the clinic to prevent tumor
progression.
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